On Monday, Oppenheimer changed its stance on Marinus (NASDAQ:MRNS) Pharmaceuticals (NASDAQ:MRNS), raising the stock from a Perform rating to Outperform. The firm also set a price target for the company at $6.00.
This upgrade comes as Marinus Pharmaceuticals recently hosted a key opinion leader (KOL) event that focused on the potential of its oral drug candidate, ganaxolone (GNX), to meet significant unmet needs in the treatment of Tuberous Sclerosis Complex (TSC).
The optimism expressed by KOLs regarding the trial design and the expected efficacy of the drug has contributed to the analyst's positive outlook. This sentiment is further supported by discussions with TSC physicians who share a consistent optimism about the drug's prospects.
The analyst highlighted several factors that underpin the upgraded rating and price target, including confidence in the Phase 3 TrustTSC trial design and its potential to demonstrate clinically meaningful efficacy.
The slower titration schedule of ganaxolone compared to the Phase 2 trial is anticipated to enhance both tolerability and effectiveness. Additionally, the positive results from the Phase 3 MARIGOLD study are seen as a favorable indicator for ganaxolone's success in the TrustTSC trial.
The analyst also noted the drug's potential to address other comorbidities associated with TSC and the expected commercial synergies with Ztalmy, another product in the company's portfolio.
The scenario analysis conducted by Oppenheimer suggests there is a more than 75% probability-adjusted upside to the stock's current value, assuming the upcoming trial results are positive. The firm anticipates that successful trial outcomes could also have implications for the treatment of other indications, further bolstering the case for the stock's upgrade. The anticipation of these topline results from the TrustTSC trial is expected in early fourth quarter of 2024.
In other recent news, Marinus Pharmaceuticals is nearing the release of key Phase 3 trial data for its seizure treatment drug, ZTALMY. The TrustTSC trial has shown promise with a low discontinuation rate and a significant reduction in seizure frequency.
Marinus anticipates filing a supplemental New Drug Application in April 2025. The company also reported net product revenues of $8 million for the second quarter, primarily due to ZTALMY.
TD Cowen has maintained its Buy rating on Marinus, in light of the company's steady revenue and upcoming Phase III trial results. The firm noted Marinus' successful challenge of a patent for IV ganaxolone, previously held by Ovid Therapeutics (NASDAQ:OVID).
Despite a reported net loss before income taxes of $35.8 million for the quarter, Marinus remains on track to meet its revenue guidance for 2024. The company is planning for the potential launch of ZTALMY for tuberous sclerosis complex in the second half of 2025, with profitability targeted within 12 to 18 months post-launch. These are among the recent developments at Marinus Pharmaceuticals.
InvestingPro Insights
With the recent upgrade by Oppenheimer, investors are closely monitoring Marinus Pharmaceuticals (NASDAQ:MRNS). According to real-time data from InvestingPro, the company has a market capitalization of $91.44 million and is experiencing notable revenue growth, with a 32.48% increase reported in the last quarter as of Q2 2024. Despite these promising numbers, Marinus Pharmaceuticals faces challenges, as reflected by its gross profit margin of -221.93% and an operating income margin of -440.11% for the same period.
InvestingPro Tips highlight that analysts have recently revised their earnings estimates upwards for the upcoming period, which could signal growing confidence in the company's future performance. However, they also caution that Marinus is quickly burning through cash and that the stock is currently in overbought territory according to the Relative Strength Index (RSI), which could suggest a potential pullback in the near term. Moreover, the company's valuation implies a poor free cash flow yield, and analysts do not expect it to be profitable this year.
For investors seeking a deeper understanding of Marinus Pharmaceuticals' financial health and stock performance, InvestingPro offers additional tips and insights. As of now, there are 12 more InvestingPro Tips available that can provide further guidance on whether to consider Marinus Pharmaceuticals as part of an investment portfolio.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.